Navigation Links
New CDC Study Confirms Effectiveness of UV-C Disinfection in Reducing Harmful Pathogens for Hospitals
Date:4/19/2013

DURHAM, N.C., April 19, 2013 /PRNewswire/ -- A recent study funded by Centers for Disease Control and Prevention (CDC) Epicenters Program and published in Infection Control and Hospital Epidemiology ( Deverick H. Anderson , M.D., MPH et al., 2013) supports and expands on previously published studies confirming the effectiveness of an automated UV-C-emitting device to combat the pathogens Clostridium difficile (C. diff.), vancomycin-resistant enterococci (VRE) and Acinetobacter spp. – some of the common culprits of health care-associated infections drawing increased attention for hospitals across the country.

It is well-documented that these pathogens, along with others such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE), can persist on environmental surfaces for days or weeks, and C. diff. spores can exist as long as five months on surfaces in hospital environments. Standard approaches to environmental cleaning have proven inadequate with studies showing that 50 percent or more of hospital surfaces go untouched during terminal room disinfection, leading to the transmission of these hardy pathogens from one patient to another. The data published by the Society of Healthcare Epidemiology of America (SHEA) concluded that an automated UV-C system capable of delivering a measured and consistent UV-C dose significantly improved terminal disinfection of patient areas in hospitals.

The only device utilized in the study is TRU-D SmartUVC™, a portable UV disinfection system unique to the market with Sensor360™ technology, which analyzes the unique contents, shape and size of the room to calculate the precise pathogen-lethal dose of UV-C light needed to properly disinfect the environment (both line-of-site and shadowed spaces). A proper dose of UV-C light modifies the DNA structure of an infectious cell so it cannot reproduce and therefore cannot colonize and spread. These results were confirmed by the study, which reported a significant decrease in the total number of colony-forming units (CFUs) of these pathogens in both direct and indirect line of sight.

"Results of TRU-D have been supported by multiple independent peer-reviewed studies conducted by leading authorities in infection control and epidemiology," said Chuck Dunn , president of Memphis-based Lumalier, maker of TRU-D SmartUVC. "We are pleased to add another reputable third-party validation of our method of automated no-touch disinfection."

The study was performed at two tertiary acute care hospitals, Duke University Medical Center and University of North Carolina Health Care, from July 2011 through September 2011. Hospital rooms utilized in the study were identified as those of patients placed on precautions as a result of colonization or infection with a target organism. Environmental cultures – from direct and indirect lines of site – were obtained on specific environmental locations within the room after patient discharge and before manual room cleaning by housekeeping personnel. TRU-D was then used in the room, and cultures were repeated in triplicate from the same environmental sites following application of the UV-C light. In total, 229 environmental surfaces were sampled in the rooms of 39 patients over the 15-month study. Following use of TRU-D, there was a calculated reduction of more than 91 percent in the total number of CFUs of any pathogen detected from all sampled sites. Additionally, a greater than 92-percent reduction was achieved for all three target organisms (97.89 percent for VRE, 92.95 percent for C. diff. and 98.07 percent for Acinetobacter), with no statistically significant differences in reductions occurring in direct versus indirect line of sight disinfection for any of these categories.

TRU-D SmartUVC™, the signature product of Memphis-based Lumalier, is the only portable UV disinfection system on the market that precisely measures reflected UVC emissions with Sensor360™ to automatically calculate the pathogen-lethal UV dose required for proper and consistent disinfection of health care environments. For information, visit www.TRU-D.com.

For more information, contact:
Kerri Guyton
Obsidian Public Relations
Phone: 662-422-8012
Email

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Lumalier
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... DUBLIN , Feb. 5, 2016 /PRNewswire/ ... the addition of the "Global Obstetrics ... company profile to their offering. ... addition of the "Global Obstetrics Partnering ... company profile to their offering. --> ...
(Date:2/4/2016)... Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... structural heart disease and critical care monitoring, announced today ... (ASR) agreement with Morgan Stanley & Co. LLC to ... is part of the Company,s previously authorized program to ... stock.  --> --> ...
(Date:2/4/2016)... Feb. 4, 2016 Worldwide Radiology Oncology ... growth as next generation systems provide a way ... for cancer surgery. New systems pinpoint the delivery ... has been such a problem previously, limiting the ... robots take cancer surgery far beyond what has ...
Breaking Medicine Technology:
(Date:2/5/2016)... SARASOTA, Fla., (PRWEB) , ... February 05, 2016 , ... ... appetizing recipes just in time for this weekend’s Big Game. Take the stress out ... ingredients that will keep your guests happy at every stage of the game. , ...
(Date:2/5/2016)... Georgia (PRWEB) , ... February 05, 2016 , ... Dr. ... to announce their 2nd Annual No Cost Dental Day to individuals in need. The ... The purpose of this No Cost Dental Day is to provide dental care to ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... Move from on one drop zone to the next using Colorize's dynamic moving camera. ... any project. This package includes a 3D slideshow environment with 1 to 5 focus ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... kitchens, recently announced the debut of their latest mobile kitchen model, featuring customizable ... organizations with modern, high-volume commercial kitchens for use anywhere in the U.S. Many ...
(Date:2/5/2016)... ... 05, 2016 , ... KICVentures ( http://www.kicventures.com ) announced today ... New York City on Thursday, January 21, 2016. Kingsley R. Chin, the ... of the varsity Columbia soccer program) spoke at the event, offering professional insight ...
Breaking Medicine News(10 mins):